Surrey Heartlands

Joint Formulary & PAD

Salmeterol (Serevent Evohaler) - Asthma

You are here : Home > Formulary Search > Salmeterol (Serevent Evohaler) - Asthma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Inhaler (Metered Dose)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
NFD1
SPC
Restrictions / Comments :
Important

Serevent Evohaler

LABA monotherapy no longer recommended for asthma or COPD.

Not for initiation in new patients.

Documentation

Webpage
How to use a metered dose inhaler (MDI) with a large volume spacer - video
Webpage
How to use a metered dose inhaler (MDI) with a small volume spacer - video
Patient resource
How to use a metered dose inhaler (MDI) - Patient information leaflet
Patient resource
How to use a metered dose inhaler (MDI) with a large volume spacer - Patient information leaflet
Patient resource
How to use a metered dose inhaler (MDI) with a small volume spacer - Patient information leaflet
Patient resource
How to use a metered dose inhaler (MDI) - video
Information
In-Check device for improving inhaler technique - Nov 16

PAD Profile

ChemicalSubstance :
Salmeterol (Serevent Evohaler)
Indication :
Asthma
Group Name :
LABA
Keywords :
LABAs, adrenoreceptor agonists, bronchodilators, long acting beta 2 agonist, respiratory, asthmatics, Selective beta2-agonists, long-acting beta agonists
Brand Names Include :
Serevent Evohaler
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Asthma
Supporting Documents :
7

Other Indications

Below are listed other indications that Salmeterol (Serevent Evohaler) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Asthma.

Committee Recommendations (1)

04 Nov 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Single device LABA is not recommended in Asthma or COPD.
Combined LAMA/LABA is the bronchodilator treatment of choice for patients with COPD who are breathless or having exacerbations following treatment with SABA.

Existing LABA patients, whose symptoms are under control, can continue with their current treatment until both they and their NHS healthcare professional agree it is appropriate to change.

Inhaler devices should be prescribed by BRAND.